Last reviewed · How we verify
Low-concentration carbohydrate
Low-concentration carbohydrate is a Small molecule drug developed by Ain Shams University. It is currently FDA-approved for Glycemic management in diabetes and prediabetes, Blood glucose control in metabolic syndrome.
Low-concentration carbohydrate formulations reduce glycemic load and postprandial blood glucose spikes by slowing carbohydrate absorption and digestion.
Low-concentration carbohydrate has been studied in relation to conditions such as Metabolic-dysfunction Associated Steatotic Liver Disease, Postprandial Hyperglycemia, and Weight Loss, often in conjunction with interventions like Low sugar diet and breakfast omission.
At a glance
| Generic name | Low-concentration carbohydrate |
|---|---|
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Low-concentration carbohydrate products are designed to deliver reduced amounts of simple sugars and refined carbohydrates, thereby minimizing rapid glucose absorption and insulin demand. This approach helps maintain more stable blood glucose levels throughout the day. Such formulations are typically used as dietary interventions or medical foods rather than pharmaceutical drugs with specific molecular targets.
Approved indications
- Glycemic management in diabetes and prediabetes
- Blood glucose control in metabolic syndrome
Common side effects
- Gastrointestinal distress
- Bloating or flatulence
Key clinical trials
- LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer (PHASE2)
- The Intensive Care Platform Trial (PHASE4)
- SMART Diets for MASLD (PHASE2)
- Caprini Score in Venous Surgery: a Prospective Cohort Study
- High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) (PHASE1)
- Ketogenic Diet for Post-Traumatic Stress Disorder (PTSD) (NA)
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PHASE2)
- Reward Sensitivity and Pharmacotherapy for Smoking Cessation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low-concentration carbohydrate CI brief — competitive landscape report
- Low-concentration carbohydrate updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about Low-concentration carbohydrate
What is Low-concentration carbohydrate?
How does Low-concentration carbohydrate work?
What is Low-concentration carbohydrate used for?
Who makes Low-concentration carbohydrate?
What development phase is Low-concentration carbohydrate in?
What are the side effects of Low-concentration carbohydrate?
Related
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Glycemic management in diabetes and prediabetes
- Indication: Drugs for Blood glucose control in metabolic syndrome
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing